On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of a single drug launch reshaping an entire business almost overnight.
A Launch That Keeps Outrunning Itself
BRINSUPRI, Insmed’s oral treatment for non-cystic fibrosis bronchiectasis, generated $309.2 million in the second quarter of 2026, up 49% from the first quarter of 2026, a pace that came without a full year of sales history to compare against. That momentum pushed Insmed to raise its full-year 2026 BRINSUPRI guidance to a range of $1.25 billion to $1.40 billion, up from its earlier target of at least $1 billion. ARIKAYCE, the company’s older inhaled antibiotic, grew a steadier 8% year over year to $116.3 million, with international sales up 19% doing most of the work while US sales barely moved.
The pipeline is where the bigger bet sits. In July, Insmed reported positive 12-month data from its open-label extension study of TPIP in pulmonary arterial hypertension, and the company is now enrolling patients in Phase 3 studies of TPIP in both PAH and pulmonary hypertension associated with interstitial lung disease. Insmed raised its peak revenue estimate for its three lead programs to more than $14 billion combined, made up of more than $7 billion for BRINSUPRI, more than $6 billion for TPIP, and more than $1 billion for ARIKAYCE. With $1.2 billion in cash, equivalents, and marketable securities as of June 30, 2026, the company has room to fund that pipeline while a Japan regulatory decision for BRINSUPRI and a US sNDA filed in July for expanded ARIKAYCE use both play out.
The Price Tag Behind The Growth
That growth is not coming cheap. Selling, general and administrative expenses jumped to $247.5 million from $154.8 million a year earlier, and research and development spending rose to $210.0 million from $177.2 million, both driven by higher headcount and the commercial buildout behind BRINSUPRI. Worth noting too is that the dramatic swing in the bottom line was not purely operational. A $99.76 million benefit from the change in fair value of contingent consideration liabilities, compared with a $59.0 million expense in the same period last year, did a lot of the work in narrowing the loss.
Shares outstanding also kept climbing, with weighted average shares rising to 217.4 million from 189.3 million, and the accumulated deficit stood at $5.8 billion as of June 30. Insmed also flagged that it is still evaluating how evolving US policy could affect the timing of future international launches. Layer on TPIP’s four separate Phase 3 programs across PAH, PH-ILD, PPF, and IPF, plus earlier-stage bets like INS1148, INS1201, INS1202, and INS1033, and the company has a lot of expensive plates spinning at once.
Where Wall Street Money Sits
Hedge fund ownership climbed from 67 to 88 funds in the most recent quarter, which points to institutional investors building positions as the BRINSUPRI numbers came in. Short interest sits at 5.62% of the float, a level that suggests a modest bear camp rather than heavy organized skepticism. Put together, rising fund ownership alongside relatively light short positioning suggests the market has grown more comfortable with the growth story than doubtful of it.
What Comes Next
Insmed’s next few quarters will show whether BRINSUPRI’s early trajectory holds up as it expands into new markets and label expansions, or whether growth cools as the launch matures. The company itself is confident enough to put a number on it, pegging its three lead programs at more than $14 billion in combined peak sales. Getting there means funding TPIP’s four separate Phase 3 programs and an expanding sales force at the same time, all while the share count keeps climbing.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
